It's Showtime for Stericycle
Stericycle (NAS: SRCL) is expected to report Q2 earnings around July 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Stericycle's revenues will expand 12.8% and EPS will expand 12.3%.
The average estimate for revenue is $529.1 million. On the bottom line, the average EPS estimate is $0.91.
Last quarter, Stericycle booked revenue of $513.8 million. GAAP reported sales were 12% higher than the prior-year quarter's $460.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.88. GAAP EPS of $0.85 for Q1 were 13% higher than the prior-year quarter's $0.75 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 47.5%, 60 basis points better than the prior-year quarter. Operating margin was 26.2%, much about the same as the prior-year quarter. Net margin was 14.5%, 40 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $2.13 billion. The average EPS estimate is $3.69.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 300 members out of 327 rating the stock outperform, and 27 members rating it underperform. Among 97 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 88 give Stericycle a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stericycle is outperform, with an average price target of $106.31.
The rich are different than you and me: They might not notice the moneymaking stories right under our noses. In our new report, "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice," we give you three Peter Lynch-inspired buy-what-you-know stocks for the 99%. Click here for instant access to this free report.
- Add Stericycle to My Watchlist.
The article It's Showtime for Stericycle originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends Stericycle. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.